Adverum

REDWOOD CITY, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today…

REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today…

- Richard Beckman, M.D., chief medical officer, transitions to…

REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum…

- Geographic atrophy (GA) program introduced with complement…

- Wet age-related macular degeneration (wet AMD) is a bilateral…

REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) --  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced…